Trial Profile
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Irinotecan (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 01 Aug 2022 Results assessing evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies published in the Cancer Chemotherapy and Pharmacology
- 15 Feb 2022 Status changed from recruiting to completed.
- 15 Oct 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.